SCHEMBL20547835

SCHEMBL20547835

Fc1cccnc1-c1ccc2ccncc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.52
MINK1 Q8N4C8 1/20 0.52
TNIK Q9UKE5 1/20 0.52
GABRA1 P14867 3/20 0.39
GABRG2 P18507 3/20 0.39
GABRB3 P28472 3/20 0.39
GABRA5 P31644 3/20 0.39
GABRA3 P34903 3/20 0.39
BRAF P15056 1/20 0.39
PIM1 P11309 3/20 0.38
NPC1 O15118 3/20 0.37
TGFBR1 P36897 2/20 0.37
TGFBR2 P37173 1/20 0.37
MAPT P10636 3/20 0.37
RAB9A P51151 2/20 0.37
TP53 P04637 1/20 0.37
CASP1 P29466 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
AR P10275 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20547736 0.76 GABRG2 (0.43) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL31269699 0.75 MAP4K4 (0.58) MAP4K4MINK1TNIKBRAFNPC1
SCHEMBL24485360 0.74 MAP4K4 (0.48) MAP4K4MINK1TNIKNPC1MAPT
SCHEMBL11992047 0.73 KDM4E (0.53) MAP4K4MINK1TNIKNPC1TGFBR1
SCHEMBL31375810 0.73 MAP4K4 (0.54) MAP4K4MINK1TNIKBRAFNPC1
SCHEMBL31025260 0.73 CSNK2A2 (0.43) NPC1MAPTRAB9ATRPV1
SCHEMBL4848530 0.73 GABRA1 (0.40) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL13911043 0.72 MAP4K4 (0.54) MAP4K4MINK1TNIKBRAFNPC1
SCHEMBL20209695 0.71 NPC1 (0.54) MAP4K4MINK1TNIKNPC1MAPT
SCHEMBL19805045 0.71 MAPT (0.70) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615537-A2 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS Novartis AG (CH) 2020-03-04 EP disclosed
WO-2018198077-A2 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS NOVARTIS AG (CH) 2018-11-01 WO disclosed